| Title |
KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 mutations in pancreatic cancer / |
| Authors |
Cicėnas, Jonas ; Kvederavičiūtė, Kotryna ; Meškinytė, Ingrida ; Meškinytė-Kaušilienė, Edita ; Skeberdytė, Aistė ; Cicėnas, Jonas |
| DOI |
10.3390/cancers9050042 |
| Full Text |
|
| Is Part of |
Cancer.. Basel : MDPI AG. 2017, Vol. 9, no 5, Art. no 42, Art. no 42 [p. 1-9].. ISSN 2072-6694 |
| Keywords [eng] |
KRAS ; TP53 ; CDKN2A ; SMAD4 ; BRCA1 ; BRCA2 ; Mutation ; Pancreatic cancer ; Genetic variant |
| Abstract [eng] |
Pancreatic cancer is a disease that has a very high fatality rate and one of the highest mortality ratios among all major cancers, remaining the fourth leading cause of cancer-related deaths in developed countries. The major treatment of pancreatic cancer is surgery; however, only 15–20% of patients are candidates for it at the diagnosis of disease. On the other hand, survival in patients, who undergo surgery, is less than 30%. In most cancers, genome stability is disturbed and pancreatic cancer is not the exception. Approximately 97% of pancreatic cancers have gene derangements, defined by point mutations, amplifications, deletions, translocations, and inversions. This review describes the most frequent genetic alterations found in pancreatic cancer. |
| Published |
Basel : MDPI AG |
| Type |
Journal article |
| Language |
English |
| Publication date |
2017 |
